Background {#Sec1}
==========

Insomnia is defined as problems with sleep initiation, consolidation, duration, or quality, despite an opportunity to sleep enough coupled with daytime impairment. Insomnia and insomnia-related symptoms are highly prevalent in adult populations, ranging from 5 to 30%, being more common among women than men and increasing with age \[[@CR1]\]. During the past decades, the prevalence of insomnia symptoms has grown both in the USA and Europe \[[@CR2]--[@CR4]\] and mounting evidence shows that insomnia is highly comorbid with psychiatric disorders, e.g., depression \[[@CR1]\]. Emerging data also suggest that insomnia constitutes a risk factor for cardiometabolic diseases \[[@CR5], [@CR6]\]. Several mechanisms have been proposed to link insomnia and cardiometabolic disease including endocrine dysregulation, inflammation, autonomic imbalance, and endothelial dysfunction \[[@CR6], [@CR7]\]. It is also suggested that subjects with insomnia symptoms engage in more adverse health behaviors such as smoking and alcohol consumption and are less physically active \[[@CR2], [@CR8]\].

Cardiorespiratory fitness (CRF) describes the capacity of the circulatory system to provide working muscles with oxygen during heavy working loads and is often expressed in terms of measured or estimated maximal oxygen consumption (VO~2~max) level \[[@CR9]\]. Higher levels of CRF have been shown to associate with numerous health benefits including reduced burden of anxiety and depression \[[@CR10]\]. Conversely, low levels of CRF predict increased cardiometabolic disease risk and all-cause mortality \[[@CR11]\].

Studies addressing the association between insomnia and CRF are sparse. In a large community-based sample, there was a moderate inverse association between self-reported insomnia symptoms and CRF, assessed by peak oxygen uptake \[[@CR12]\]. The total score on the Insomnia Severity Index (ISI) questionnaire was inversely associated with self-perceived fitness in a cohort of students \[[@CR13]\]. Therefore, in the current study, we aimed to investigate the association between insomnia classified by ISI and CRF assessed by a submaximal exercise test in a population-based sample of middle-aged, urban Swedish men and women. We hypothesized that insomnia is associated with decreased VO~2~max, independently of objectively measured physical activity level.

Material and methods {#Sec2}
====================

Overview of the study cohort {#Sec3}
----------------------------

The Swedish CArdioPulmonary bioImage Study (SCAPIS) is an ongoing national multicenter study with the focus on identification and investigation of cardiometabolic disease and related mechanisms in a cohort of 30,000 men and women, aged 50 to 64 years \[[@CR14]\]. In 2012, a comprehensive pilot trial was conducted at the Sahlgrenska University Hospital in Gothenburg, Sweden, to examine the feasibility and financial and ethical consequences of SCAPIS. In detail, 2243 subjects were randomly selected from the Swedish population register stratified for low and high socioeconomic status (SES) area and 1111 agreed to participate. Participants underwent a 2-day protocol including imaging and functional tests of the heart, lungs, and metabolism as well as extensive health questionnaires. In addition, participants were asked to perform a submaximal fitness test and to wear an accelerometer during 7 days to objectively record daily physical activity. All participants gave their written informed consent and SCAPIS has been approved as a multicenter study by the ethics committee at Umeå University (Dnr 2010-228-31M). The protocol for the current study was approved by the regional Ethics Committee of Gothenburg (Dnr 638-16).

Insomnia and sleep duration {#Sec4}
---------------------------

The Insomnia Severity Index questionnaire was used to classify insomnia \[[@CR15]\]. The ISI consists of 7 questions assessing the nature, severity, and impact of insomnia (total score ranges from 0 to 28). A cutoff of ISI score ≥ 10 was applied for insomnia diagnosis \[[@CR16]\]. Subjective sleep duration was assessed by the question: "How many hours do you usually sleep during 24-hours" with response alternatives: "4 hours or less; 5 hours; 6 hours; 7 hours; 8 hours; 9 hours; 10 hours or more," further divided into a categorical variable "subjective sleep duration \< 6 hours" yes or no.

Cardiorespiratory fitness and physical activity {#Sec5}
-----------------------------------------------

Participants were invited to participate in a submaximal cycle ergometer exercise test for the assessment of VO~2~max. The test followed the Ekblom-Bak cycle ergometer protocol for adults \[[@CR17]\] and included 4 min cycling (Monark ergometer 828E, Monark Exercise AB, Vansbro, Sweden) at two different workloads, respectively. The first workload was standard and low work rate (\~ 30 W) and the second a higher, individually chosen work rate aiming for a perceived exertion of approximately 14 on the Borg scale \[[@CR18]\]. The mean heart rate (Polar Electro Oy, Kempele, Finland) during the last minute at the low and high workload was recorded respectively. VO~2~max was estimated based on the difference in workload and heart rate between the two workloads using validated gender-specific equations \[[@CR19]\]. Subjects with diagnosed heart condition, taking beta-adrenergic blockers, having pain in hips, back, or knees, with obesity or perceived inability to perform the test were excluded from the test.

Objective measurement of physical activity in the SCAPIS pilot trial has been described in detail previously \[[@CR20]\]. Briefly, participants were instructed to wear the triaxial accelerometers (ActiGraph GT3X and GT3X+, Actigraph, LCC, Pensacola, FL, USA) on the right hip for seven consecutive days during waking hours but not when in water-based activities. Sampling frequency was set at 30 Hz and data were downloaded using the ActiLife software (v. 6.10.1, Actigrah LCC, Pensacola, FL, USA) as 60-s epochs with low frequency extension filtering. Participants with at least 600 min of accelerometer wear time for at least 4 days were accepted to be included in analyses. The vector magnitude counts per minute (cpm) were used to classify time spent sedentary (SED: 0--199 cpm) and moderate to vigorous intensity physical activity (MVPA: ≥ 2690 cpm) \[[@CR21], [@CR22]\]. Data for SED and MVPA are shown as mean daily percentage over the measurement period.

Information on lifestyle, living conditions, and comorbidities {#Sec6}
--------------------------------------------------------------

Weight (kg), height (m), and waist circumference (cm) were measured prior to the fitness test. Body mass index (BMI) was calculated as weight divided by square height (kg/m^2^). Self-reported smoking habit was classified as never smoker, occasional smoker, former smoker, and current active smoker. Alcohol consumption was assessed using the Alcohol Use Disorders Identification Test consumption (AUDIT-c) questionnaire where a total score of 5 or higher in men and 4 or higher in women was classified as risk drinking \[[@CR23]\].

University education (yes; no) was used to describe the subjects' education level. Participants were asked if they currently are engaged in an income-related job or not.

Self-reported chronic disease was identified for subjects who reported one or more of the following: diagnosed diabetes, cancer, or COPD, previous bypass surgery or hospitalization because of myocardial infarction/stroke. The question "Have you ever had clinically diagnosed sleep apnea (yes/no)?" was used to identify subjects with comorbid sleep apnea. Information about depression symptoms was based on the question: "During the past 12 months, have you experienced a period of two or more than two weeks when you have felt sad, downhearted or depressed? (yes/no)."

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS 25.0 (IBM, Armonk, NY, USA). Data are shown as mean (SD) or median \[interquartile range IQR\]. Distribution of the variables was analyzed using Kolmogorov-Smirnov test. Chi-square tests were used to compare categorical variables. Normally distributed variables were compared using independent sample *t* test and Mann-Whitney test was applied for non-normally distributed data comparison. Effect size of the independent *t* test was determined by Cohen's d. The association between insomnia and CRF was analyzed using generalized linear models, adjusting for age, gender, BMI, waist circumference, SES, university education, income-related job, smoking, risky drinking, chronic disease, sleep apnea, depression symptoms, sleep duration \< 6 h, percentage of MVPA, and percentage of SED. Subgroup analyses were performed stratified by gender. Sensitivity analyses were performed by excluding participants who reported symptoms of depression or were identified with chronic disease. A *p* value \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Description of the study population {#Sec9}
-----------------------------------

Out of 1111 subjects in the SCAPIS pilot study, 795 participants (71.6% of full sample) performed a submaximal cycle ergometer exercise test. Of these subjects, 82 subjects had no/incomplete ISI score, 74 did not complete the accelerometer test, and 15 subjects lacked both assessments. Six hundred twenty-four had complete information on both the ISI questionnaire and the objectively measured physical activity. Subjects with missing information on income-related job, risky drinking, self-reported chronic disease/sleep apnea/depression symptoms, or subjective sleep duration were further excluded from the analyses (*n* = 21). The final cohort included 603 subjects (289 men; mean age 57 ± 4 years; BMI 26.8 ± 4.0 kg/m^2^).

Non-response analysis {#Sec10}
---------------------

Compared to the final cohort the excluded subjects were slightly older, more overweight, more sedentary and more often current smokers. As expected, self-reported chronic disease, depression symptoms, insomnia, low socioeconomic status, and no university degree as well as no income-related job were more prevalent among these subjects (supplementary table [1](#MOESM1){ref-type="media"}). There were no significant differences in VO~2~max or MVPA between the two groups.

Insomnia vs. non-insomnia {#Sec11}
-------------------------

The prevalence of insomnia (ISI ≥ 10) was 31.8% in this middle-aged population. The median ISI score in men and women was 6 \[IQR 2 to 10\] and 7 \[4 to 12\], respectively (Mann-Whitney test, *p* \< 0.001). The proportion of ISI \< 10 in women and men was 64.3% and 72.3%, respectively. As expected, insomnia was more prevalent among women than men (35.7% vs. 27.7%, *p* = 0.035). Compared to the non-insomnia group, there was a higher proportion of low socioeconomic status, no income-related job and depression symptoms in the insomnia group (all *p* \< 0.01). There were no significant differences in objectively measured physical activity (MVPA) or SED between the groups. However, VO~2~max was lower in insomnia compared to non-insomnia subjects (31.2 ± 6.3 vs. 32.4 ± 6.5 ml \*kg^−1^ \*min^−1^, *p* = 0.028, Cohen's *d* = 0.49, Table [1](#Tab1){ref-type="table"}). Insomnia was consistently associated with lower VO~2~max across the tertiles of MVPA, and VO~2~max showed a significant difference in subjects with the highest MVPA level (Fig. [1](#Fig1){ref-type="fig"}).Table 1Characteristics of the studied cohort by insomnia status (*n* = 603)TotalInsomnia severity index \< 10 (*n* = 411)Insomnia severity index ≥ 10 (*n* = 192)*p* value for comparisonMen (%)47.950.941.7*0.035*Age (years)57.2 (4.4)57.4 (4.4)56.9 (4.1)0.148Body mass index (kg/m^2^)26.8 (4.0)26.6 (3.9)27.2 (4.3)0.137Waist circumference (cm)93.7 (11.4)93.7 (11.5)93.7 (11.3)0.989Low socioeconomic status (%)39.835.848.4*0.003*University degree (%)42.645.337.00.056No income-related job (%)17.413.625.5*\< 0.001*Smoking (%) Never47.148.943.20.339 Occasional2.83.22.1 Former40.038.942.2 Current10.19.012.5Risky alcohol consumption (%)28.927.531.80.280Subjective sleep duration *\<* 6 h (%)9.03.221.4*\< 0.001*Sleep apnea (%)4.33.95.20.459Chronic disease (%)10.99.514.10.094Depression symptoms (%)24.016.141.1*\< 0.001*Percentage MVPA5.7 \[3.7\]5.5 \[3.6\]5.9 \[3.6\]0.358Percentage SED52.6 (9.8)52.4 (9.9)52.8 (9.6)0.616VO~2~max (ml \*min^−1^ \*kg^−1^)32.0 (6.5)32.4 (6.5)31.2 (6.3)*0.028*Data show as mean (SD) or median \[inter quartile range\]. Chronic disease includes stroke, coronary artery disease, diabetes, cancer, and COPDSignificant *p* value presented in italics*MVPA* moderate to vigorous intensity physical activity, *SED* time spent sedentaryFig. 1VO~2~max by insomnia and non-insomnia groups across MVPA tertiles

The association between insomnia and VO~2~max {#Sec12}
---------------------------------------------

In a multivariate generalized linear model, insomnia status was not independently associated with VO~2~max (*β* = − 0.56, 95% CI − 1.31--0.20, *p* = 0.148) controlling for age, gender, BMI, waist circumference, SES, university education, income-related job, smoking, risky alcohol consumption, subjective short sleep duration \< 6 h, depression symptoms, self-reported chronic disease, sleep apnea, percentage of MVPA, and percentage of SED (Table [2](#Tab2){ref-type="table"}). However, in a gender-stratified multivariate analysis, insomnia was significantly associated with lower VO~2~max in men (*β* = − 1.15, 95% CI − 2.23--− 0.06, *p* = 0.038), but not in women (*β* = − 0.09, 95% CI −1.09--0.92, *p* = 0.866) (Table [3](#Tab3){ref-type="table"}).Table 2Multivariate generalized linear model for VO~2~max prediction in the full sample (*n* = 603)*β*-coefficients (95% CI)*p* valueMen vs. women*7.47 (6.64--8.30)\< 0.001*Age (years)*− 0.32 (− 0.40--− 0.25)\< 0.001*BMI (kg/m^2^)*− 0.50 (− 0.66--− 0.33)\< 0.001*Waist circumference (cm)*− 0.16 (− 0.22--− 0.10)\< 0.001*Low vs. high socioeconomic status*− 1.30 (− 2.02--− 0.59)\< 0.001*With vs. without university education*0.97 (0.27--1.67)0.007*Without vs. with income-related job0.68 (*−* 0.24--1.60)0.146Smoking Occasional vs. never1.15 (*−* 0.84--3.13)0.257 Former vs. never*−* 0.12 (*−* 0.83--0.60)0.753 Current vs. never0.02 (*−* 1.14--1.18)0.978Risky vs. not risky alcohol consumption0.42 (*−* 0.32--1.16)0.265Insomnia vs. non-insomnia*−* 0.56 (*−* 1.31--0.20)0.148Subjective sleep duration *\<* 6 h vs. ≥ 6 h0.55 (*−* 0.66--1.75)0.377Sleep apnea vs. no apnea1.51 (*−* 0.13--3.15)0.071Chronic disease vs. no disease*−* 0.45 (*−* 1.49--0.58)0.390Depression symptoms vs. no symptoms0.43 (*−* 0.37--1.23)0.293Percentage (%) MVPA*0.24 (0.12--0.37)\< 0.001*Percentage (%) SED0.01 (*−* 0.03--0.05)0.541Chronic disease includes stroke, coronary artery disease, diabetes, cancer, and COPDSignificant *p* value presented in italics*MVPA* moderate to vigorous intensity physical activity, *SED* time spent sedentaryTable 3Multivariate generalized linear model for VO2max prediction stratified by genderMen (*n* = 289)*β*-coefficient (95% CI)*p* valueInsomnia vs. non-insomnia*− 1.15 (− 2.23--− 0.06)0.038*Women (*n* = 314)*β*-coefficient (95% CI)*p* valueInsomnia vs. non-insomnia*−* 0.09 (*−* 1.09--0.92)0.866Adjusting for age, body mass index, waist circumference, socioeconomic status, university education, income-related job, smoking, risky drinking, chronic disease (including stroke, coronary artery disease, diabetes, cancer, and COPD), sleep apnea, depression symptoms, sleep duration *\<* 6 h, percentage of moderate to vigorous intensity physical activity, and percentage of time spent sedentarySignificant *p* value presented in italics

Sensitivity analyses {#Sec13}
--------------------

In a repeated sensitivity analysis excluding 66 subjects with self-reported chronic disease, the result between insomnia and VO~2~max remained unchanged (supplementary tables [2](#MOESM1){ref-type="media"} and [3](#MOESM1){ref-type="media"}). Similarly, when excluding subjects with self-reported symptoms of depression (*n* = 145), the association between insomnia and lower VO~2~max in men was preserved (supplementary tables [4](#MOESM1){ref-type="media"} and [5](#MOESM1){ref-type="media"}).

Discussion {#Sec14}
==========

In this middle-aged gender-balanced cohort, insomnia detected by ISI score ≥ 10 was associated with lower CRF, particularly in men. This association was independent of SES, body composition, comorbidity, and lifestyle including MVPA. To the best of our knowledge, this is the first study using a valid insomnia diagnosis instrument rather than insomnia symptoms to address the link between CRF and insomnia. It is argued that in relation to, and possibly in addition to, unhealthy lifestyle (e.g., physical inactivity) low CRF may constitute an important link to increased cardiometabolic risk in insomnia.

Both physical activity and CRF provide strong prognostic ability for future cardiovascular disease. CRF is moderately related to the intense aspect of habitual physical activity and has been observed to be a stronger predictor of cardiovascular events and mortality than physical activity \[[@CR24], [@CR25]\]. Although the insomnia--low physical activity association has been well studied, the relationship between insomnia and CRF remains less explored. Regular moderate to vigorous exercise may increase sleep time and improve sleep consolidation through mechanisms such as altered body core temperature and increased brain-derived neurotropic factor activity \[[@CR26]\]. Physical exercise induces an acute rise, but over longer term reduction, of growth hormone and testosterone levels. The magnitude of this response is influenced by factors such as previous exercise levels, age, and nutritional status \[[@CR27], [@CR28]\]. The role of an increase in growth hormone level for the subsequent night sleep is inconclusive and it remains uncertain whether physical exercise can alter the circadian fluctuations in hormone levels including testosterone and cortisol \[[@CR29]\]. Nevertheless, elevated sympathetic activity, increased cortisol levels, and inflammation caused by insomnia may lead to lowered alertness, mood disorders, and higher rate of perceived exertion which may limit physical performance by reduced effort \[[@CR26]\].

Indeed, a lower CRF in insomnia, as compared with non-insomnia subjects, was observed in the current study indicating that insomnia as a chronic disease may influence the complex biological processes involving the integrative coordination of multiple physiological systems for O~2~ metabolism and transport. In gender-specific analyses, an inverse association between insomnia and CRF was found in men but not in women. The exact explanation of this gender-specific effect is unclear. However, it is known that subjects who participated in the fitness test are generally healthier than those not participating, due to the exclusion criteria applied for the exercise test. In the current study, the prevalence of insomnia was lower in the included women compared to women excluded from the analyses. This may have reduced the power to detect a significant association between insomnia and CRF in women.

The ISI used in the current study provides a more comprehensive assessment of nighttime and daytime components of insomnia compared with information on insomnia symptoms alone. An ISI cutoff of 10 has been shown to detect insomnia cases in a community sample with 86% sensitivity and 88% specificity \[[@CR16]\]. The prevalence of insomnia in the current study is comparable to that reported in a Swedish population--based survey \[[@CR30]\]. In line with other epidemiological studies, we found that female gender, low social economy status, no income-related job, and depression symptoms were overrepresented in the insomnia group \[[@CR1]\]. In our study, more than 20% of the subjects with insomnia reported a sleep duration of less than 6 h similar to another population-based study \[[@CR31]\]. Short sleep duration has been shown to independently predict cardiovascular morbidity \[[@CR5], [@CR32]\], and it was argued that studies on insomnia and cardiovascular disease should take into account the impact of short habitual sleep time \[[@CR33]\]. Therefore, we included subjective short sleep duration in our multivariate analysis and an independent association between insomnia and CRF remained, in men.

The observed difference (1.15 ml\* kg^−1^ \*min^−1^) in CRF between the male insomnia and non-insomnia groups is modest but of clinical relevance. The age-related decline in VO~2~max has been reported to be 0.26 ml \*kg^−1^ \*min^−^1 per year in men \[[@CR34]\]. A meta-analysis of 102,980 healthy men and women indicated that each 3.5 ml \*kg^−1^ \*min^−1^ increase in CRF is associated with a 13% lower risk of all-cause mortality and 15% lower risk of cardiovascular morbidity \[[@CR11]\]. It has also been shown that men with CRF corresponding to the lowest quintile have a substantially greater risk for all-cause mortality as compared with men with moderate or high levels of CRF \[[@CR35], [@CR36]\]. A recent statement from the American Heart Association has emphasized the importance of CRF assessment in clinical practice, either by measurement or estimation, in order to optimize the prevention and treatment of cardiovascular disease \[[@CR10]\]. In the current study, a submaximal cycle ergometer test was applied instead of a maximal protocol with ventilatory gas analyses in order to increase the feasibility of the protocol in the population-based setting. A newly developed equation with improved validity was used for VO~2~max estimation \[[@CR19]\]. It is believed that this approach enables a more representative cohort and increases the generalizability of the result.

Despite the gender-balanced design, inclusion of submaximal exercise testing and objectively measured physical activity, our study also comes with limitations. Despite the fact that ISI is a valid diagnostic instrument for insomnia, the intensity and duration of the disease are not addressed. Although adequate, the use of an ISI cutoff of 10 could have led to an identification of more subjects with mild insomnia in the current study. This could, in part, have attributed to the small difference in VO~2~max observed in the insomnia and non-insomnia groups. Depression symptoms and sleep apnea were assessed by single questions rather than by validated questionnaires. The cross-sectional design of the current study does not allow any conclusions on causality for the relationship between insomnia and CRF. It has recently been shown that a decline in CRF increases the odds of incident sleep complaints \[[@CR37]\]. Whether the observed difference in VO~2~max between insomnia and non-insomnia men is due to altered physiological adaptation to physical activity needs to be further studied. Finally, the age range of the cohort may limit the generalizability of the results. Prospective studies with larger age range and detailed mapping of insomnia subtype are warranted to further elucidate the relationship between insomnia and CRF.

Conclusion {#Sec15}
==========

In this urban mid-aged Swedish population, we demonstrated that insomnia is associated with lower CRF in men, independent of body composition, living conditions, comorbidity, and lifestyle, including objectively assessed physical activity. CRF represents the body's adaptability to physical exertion which may be limited by insomnia. In light of the strong association between low CRF and increased cardiometabolic disease risk, our results provide a possible link of insomnia to cardiovascular morbidity and mortality.

Electronic supplementary material
=================================

 {#Sec16}

ESM 1(DOCX 25.5 kb)

**Comments**

This study shows in a relatively large cohort of the middle-aged population (50--64 years) the small but for public health relevant effect of lower cardiorespiratory fitness in men with insomina independent of physical activity sedentary time. The reason of non-association in women remains unclear and should be a focus in further research.
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